Topic

Articles

Previewing executive trends thought of by leaders in the pharma industry.

New Views Point the Way

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Our Launch-Time Menu

Sheila Thorne is the President/CEO, Multicultural Healthcare Marketing Group, LLC, and is one of the nation's leading experts in multicultural healthcare marketing. For more information logo onto www.sheilathorne.com

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

The Cultural Deficit in the Pharma Industry in the Era of COVID-19

COVID-19 has only magnified well known flaws of our healthcare system. An extension of Medicare is the affordable solution, writes Bruno Delagneau, and pharma needs to start planning for this to minimize its impact on US revenues.

Extension of Medicare is the Affordable Solution to Current Healthcare Problems

Dr. Manuel Hermosilla shares his thoughts on how the pharmaceutical industry reacts to challenges that arise during trials, specifically during the search for an effective COVID-19 vaccine.

The Impact of Accelerated Drug Development

How “Contractual Genericization” could revitalize pharma and reframe the public conversation.

Pricing, Innovation, and a Pound of Flesh

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

Will the Industry Rise to the Occasion?

Jill Wechsler is Pharm Exec's Washington Corespondent

While scientists are striving to discover and produce safe and effective vaccines to halt the coronovirus outbreak, anti-vacciners are revving up misinformation campaigns.

Vaccine “Hesitancy” Threatens COVID Immunization Efforts

Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.   

Master the Science of Success

Anil Soni is Head of Global Infectious Diseases at Mylan. He was closely involved in the early years of the Global Fund to Fight AIDS, Tuberculosis and Malaria, serving as the Advisor to the Executive Director from 2002-2004 and the Founding Executive Director of Friends of the Global Fight, in Washington, DC, from 2004-2005. He later served as the Chief Executive Officer of the Clinton Health Access Initiative.Ya’ir Aizenman is US and European Director for Infectious Disease at Mylan. Prior to Mylan, he was a Franklin Fellow with the U.S. Department of State, where he worked alongside colleagues in the office of the Senior Advisor for International Development and the President’s Emergency Program for AIDS Relief. 

The US could theoretically treat every single American living with HIV without spending an extra dollar on drugs. And President Trump can broker a deal to do it, write Anil Soni and Ya’ir Aizenman.

Opinion